China Advances Cancer Fight with CSPC Pharma's mRNA Therapy Trials Approval
CSPC gets China approval for clinical trial of mRNA-based cancer cell therapy, SYS6020.
Breaking News
Jun 26, 2024
Mrudula Kulkarni

CSPC Pharmaceutical Group (1093.HK) has announced regulatory
approval in China for a new human clinical trial of its cancer cell therapy
utilizing synthetic messenger RNA (mRNA) technology. This development follows
the Chinese drugmaker's earlier research into mRNA for COVID-19 vaccines,
prompting further exploration into applications such as cancer treatment
alongside several other Chinese pharmaceutical companies.
CSPC said, “The clinical trial approval obtained for the
product marks the first significant achievement of the Group in the field of
cell therapy”, clicking on a fresh tab within a stock exchange filing unveils
the endorsement from the China National Medical Products Administration. A CSPC
spokesperson declined to provide immediate answers to Reuters inquiries
regarding the technology employed in SYS6020, touted as the "world’s first
mRNA-LNP-based cell therapy product approved for clinical trials.”